Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Perrigo to focus on OTCs, nutritionals with planned sale of personal care operation.

This article was originally published in The Tan Sheet

Executive Summary

PERRIGO TO FOCUS ON OTC, NUTRITIONAL BUSINESSES through the divestiture of its $200 mil. personal care operations, the company announced June 29. The Allegan, Mich.-based private labeler's plan to divest personal care is part of a greater management restructuring to help Perrigo improve its margins and enhance its profitability. The personal care business has been Perrigo's second largest after OTCs, with sales of $526.5 mil., and followed by nutritionals, with sales of $110.4 mil. Perrigo has retained the investment banking firm J.P. Morgan to explore "strategic options to maximize the sale value of the personal care business."

You may also be interested in...

Perrigo's $190 Mil. Personal Care Unit Going To Cumberland Swan Holdings

Perrigo has signed an agreement in principle to sell its $190 mil. personal care business for an undisclosed amount to newly formed Cumberland Swan Holdings, Inc., the private labeler announced July 19. Execution of a definitive purchase agreement is expected to occur within 30 days. Proceeds will be dedicated to Perrigo's OTC and nutritional businesses.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts